SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasing overall survival in patients with castration-resistant prostate cancer whether or not they …

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was asymptomatic or mildly symptomatic and had not been treated with chemotherapy in the …

SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2014 ASCO Genitourinary Cancers Conference. Professor Bernard Escudier MD from the …

SAN FRANCISCO—The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies — just as it is in patients overall — according to …

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of abiraterone acetate therapy presented at the 2014 ASCO Genitourinary Cancers Symposium. …

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at least 30 per …

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo — though radiographic progression-free survival was improved. …

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced …

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting in New Orleans. Dr. Raymond S Wong MD, PhD — who is a hematology …